Overview
Apr 7, 2016Founded1
Compare with Black Diamond Therapeutics, Inc., Compugen Ltd. or Cellectis, or pick any stock.
- TickerVIR on Nasdaq1
- Industrybiotechnology industry1
- HeadquartersSan Francisco1
- Websitewww.vir.bio
- Incorporated inDE3
- Business address1800 Owens Street, Suite 900, San Francisco, Ca 941583
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-699.2%Operating margin5
-638.9%Net margin5
-7.6%Revenue growth, 20255
-57.2%Return on equity5
-$396.6MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Other Revenue brought in 62% of the revenue VIR Biotechnology broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Other Revenue | $2.1M | $2.3M | $3.4M |
| Grant | $46.7M | $10.5M | $2.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$26.0K
- Research and development83¢$456.0M
- Selling, general and admin17¢$92.1M
- Income tax0¢$217.0K
Out of $68.6M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $68.6M | $74.2M | $86.2M |
| Cost of revenue | $26.0K | $845.0K | $2.8M |
| Research and development | $456.0M | $506.5M | $579.7M |
| Selling, general and administrative | $92.1M | $119.0M | $174.4M |
| Restructuring, long-lived assets impairment and related charges, net | -$182.0K | $35.0M | $13.6M |
| Total operating expenses | $547.9M | $661.4M | $770.5M |
| Loss from operations | -$479.3M | -$587.2M | -$684.3M |
| Change in fair value of equity investments | $1.7M | -$5.5M | -$21.9M |
| Interest income | $40.2M | $71.8M | $87.0M |
| Other expense, net | -$409.0K | -$2.2M | -$9.0M |
| Total other income | $41.6M | $64.1M | $56.1M |
| Loss before (provision for) benefit from income taxes | -$437.8M | -$523.1M | -$628.2M |
| (Provision for) benefit from income taxes | -$217.0K | $1.1M | $13.1M |
| Net loss | -$438.0M | -$522.0M | -$615.1M |
| Net loss attributable to noncontrolling interest | $0 | $0 | -$56.0K |
| Net loss attributable to Vir Bio | -$438.0M | -$522.0M | -$615.1M |
| Net loss per share attributable to VirBio, basic (in USD per share) | -$3.16 | -$3.83 | -$4.59 |
| Net loss per share attributable to VirBio, diluted (in USD per share) | -$3.16 | -$3.83 | -$4.59 |
| Weighted-average shares outstanding, basic (in shares) | 138.5M shares | 136.2M shares | 134.1M shares |
| Weighted-average shares outstanding, diluted (in shares) | 138.5M shares | 136.2M shares | 134.1M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $232.2M | $222.9M | $241.6M |
| Short-term investments | $228.8M | $678.1M | |
| Restricted cash and cash equivalents, current | $1.9M | $89.4M | $13.3M |
| Equity investments | $6.1M | $4.3M | |
| Prepaid expenses and other current assets | $45.1M | $47.7M | |
| Total current assets | $514.1M | $1.0B | |
| Intangible assets, net | $7.8M | $8.1M | |
| Goodwill | $16.9M | $16.9M | |
| Property and equipment, net | $55.6M | $63.2M | |
| Operating right-of-use assets | $62.1M | $59.7M | |
| Restricted cash and cash equivalents, noncurrent | $7.0M | $6.4M | $6.4M |
| Long-term investments | $314.6M | $190.0M | |
| Other assets | $24.7M | $12.1M | |
| TOTAL ASSETS | $1.0B | $1.4B | |
| Accounts payable | $9.8M | $5.1M | |
| Accrued and other liabilities | $83.0M | $98.5M | |
| Contingent consideration obligation, current | $0 | $16.1M | |
| Total current liabilities | $92.8M | $119.7M | |
| Operating lease liabilities, noncurrent | $89.1M | $90.1M | |
| Contingent consideration obligation, noncurrent | $34.1M | $24.1M | |
| Other long-term liabilities | $21.6M | $14.6M | |
| TOTAL LIABILITIES | $237.5M | $248.4M | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 139,474,954 and 136,959,446 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $14.0K | $14.0K | |
| Additional paid-in capital | $2.0B | $1.9B | |
| Accumulated other comprehensive loss | -$2.1M | -$1.7M | |
| Accumulated deficit | -$1.2B | -$759.8M | |
| TOTAL STOCKHOLDERS EQUITY | $765.3M | $1.2B | $1.6B |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $1.0B | $1.4B | |
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in USD per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 139.5M shares | 137.0M shares | |
| Common stock, shares outstanding (in shares) | 139.5M shares | 137.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$438.0M | -$522.0M | -$615.1M |
| Depreciation and amortization | $11.7M | $14.6M | $19.5M |
| Amortization of premiums (accretion of discounts) on investments, net | $9.5M | $5.4M | -$8.7M |
| Noncash lease expense | $5.0M | $5.2M | $7.7M |
| Change in fair value of equity investments | -$1.7M | $5.5M | $21.9M |
| Change in estimated fair value of contingent consideration | $11.5M | $14.1M | $1.0M |
| Payment of contingent consideration in excess of acquisition date fair value | -$17.1M | $0 | $0 |
| Stock-based compensation | $49.1M | $78.5M | $111.3M |
| In-process research and development impairment | $0 | $14.6M | $9.7M |
| Non-cash restructuring, long-lived assets impairment and related charges | $654.0K | $24.2M | $7.7M |
| Other non-cash items, net | $172.0K | -$3.1M | -$910.0K |
| Prepaid expenses and other current assets | $2.1M | $4.4M | $36.3M |
| Other assets | -$12.6M | $353.0K | $2.2M |
| Accounts payable | $5.0M | -$988.0K | $732.0K |
| Accrued liabilities and other long-term liabilities | -$9.5M | -$64.0M | -$358.8M |
| Operating lease liabilities | -$7.4M | -$23.0M | -$13.0M |
| Net cash used in operating activities | -$391.8M | -$446.4M | -$778.8M |
| Proceeds from sale of equipment | $253.0K | $3.4M | $0 |
| Purchases of long-lived assets | -$4.8M | -$7.3M | -$21.6M |
| Purchases of investments | -$886.3M | -$1.2B | -$2.0B |
| Maturities and sales of investments | $1.2B | $1.7B | $2.2B |
| Net cash provided by investing activities | $310.4M | $499.4M | $164.6M |
| Proceeds from exercise of stock options | $1.3M | $790.0K | $3.5M |
| Proceeds from issuance of common stock under ESPP | $2.8M | $3.8M | $4.3M |
| Other financing activities | -$361.0K | -$165.0K | -$287.0K |
| Net cash provided by financing activities | $3.8M | $4.4M | $7.5M |
| Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | -$77.6M | $57.4M | -$606.7M |
| Operating lease liabilities obtained in exchange of right-of-use asset | $7.3M | $0 | $0 |
Leadership
Who has led VIR Biotechnology, and when. Pick a name to see everywhere that person has worked.
Chief executive
20202025
- Chief executive officerGeorge Scangos Jan 2017 to now1
Board members and other officers (1)
- Board memberMegan J Smithey Jul 2018 to now1
Subsidiaries and ownership
Subsidiaries
- Vir Biotechnology (Switzerland)
From Wikidata.1
Timeline
Recent filings
- Oct 14, 20268-K
- Oct 8, 20268-K
- Oct 6, 20263
- Oct 1, 20268-K
- Sep 17, 2026144
- Sep 9, 2026144
- Aug 25, 2026144
- Aug 24, 2026144
- Aug 21, 2026144
- Aug 12, 20264
- Aug 7, 2026SCHEDULE 13G
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 31, 2026SCHEDULE 13G/A
- Jul 24, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.vir.bio1
- WikidataQ77083018
- SEC EDGARCIK 1706431
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataVIR Biotechnology on Wikidata
- 2
- 3
- 4Company websiteVIR Biotechnology photo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12